The healthcare sector has been greatly challenged by the current pandemic, exposing the hidden weaknesses of services providers and pharmaceutical companies that have not committed to building their digital capability.
The potential for growth in the healthcare industry in Southeast Asia remains strong, with the industry previously forecasted to reach a value of US$134.2 billion in 2020*, fuelled by rapid economic growth, a thriving medical tourism industry, and an aging population.
2020 has seen the industry come under strain. Beyond manpower issues and a prevalence of chronic diseases, the industry's capabilities and capacity to adapt and scale were tested heavily by COVID-19, which stretched resources, halted medical tourism and forced the public to put off treatment for afflictions not related to the pandemic.
Healthcare service providers, pharmaceutical companies, and supply chains have all been disrupted in unprecedented ways, exposing hidden weaknesses and deficiencies in their digital capabilities.